Bristol Myers Squibb takes another late-stage loss for Opdivo-Yervoy combo in head and neck cancer
Bristol Myers Squibb has worked overtime to hunt down an edge for its PD-(L)1 blocker Opdivo over rival Keytruda from Merck, including taking a bold combo strategy with CTLA4 inhibitor Yervoy. But in head and neck cancer, the combo keeps dropping duds.
Opdivo plus Yervoy failed to show clinical benefit in extending the lives of first-line patients with recurrent or metastatic squamous cell carcinoma of the head and neck, according to topline results from the Phase III CHECKMATE-651 study revealed Friday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.